CTN Page Sitemap
- Accessibility
- April Semi-annual meetings
- Career Opportunities
- Contact Us
- Core Research Areas
- CTN awards seven postdoctoral fellowships for 2010-2011
- Disclaimer
- Donate to the CTN
- Email Service
- Event Registration
- Meetings transactions
- October semi-annual meetings
- Registration Cancelled
- Registration cancelled
- Satellite site map
- scheduler-calendar
- Search
- Search Canadian HIV Trials Database
- Thank You
- Thank You
- Transactions
- Home
- About Us
- Clinical Studies
- Enrolling
- CTN 147: Early versus delayed Pneumococcal vaccination
- CTN 198
- CTN 214: Effect of a one-year course of HAART in acute/early HIV
- CTN 216: Argon plasma coagulation for anal dysplasia in MSM
- CTN 222: Canadian co-infection cohort
- CTN 233
- CTN 236 HPV VLP vaccine in a cohort of HIV positive girls and women
- CTN 238: The MAINTAIN study
- CTN 240: VALIDATE
- CTN 242: The Canadian observational cohort (CANOC) study
- CTN 244: STOP HIV & AIDS in IDU
- CTN 246
- CTN 247: Canadian cohort of HIV+ slow progressors
- CTN 253: H1N1 flu vaccine study in HIV-positive adults
- CTN 254: Inflammation as a predictor of HIV disease progression
- CTN 256 – Phase IIB study of efficacy and safety of AGS-004
- CTN 257: Impact of HIV on mucosa
- CTN 260: Raltegravir switch study
- CTNPT 001: Fracture case-control study in HIV
- CTNPT 002: Impact of counselling on sexual risk behaviours
- CTNPT 003: Bone and renal outcomes in tenofovir exposed infants
- CTNPT 004: Effects of HLA allele frequencies on HIV disease progression
- CTNPT 005: Measuring cognition in HIV
- CTNPT 006: The Niaspan® study
- CTNPT 011: Monitoring penicillin levels for syphilis
- Ongoing
- Other studies
- Expanded Access
- Trial Results
- CTN 110: Subcutaneous interleukin-2 in the setting of HIV infection
- CTN 145 : rIL-2 to slow progression of HIV (SILCAAT)
- CTN 167: Options with antiretrovirals (OPTIMA)
- CTN 173: Vaccination before treatment interruption
- CTN 190: Strategies for management of ART (SMART)
- CTN 203
- CTN 205: Valproic acid and HIV
- CTN 221
- CTN 227: Hepatitis C therapeutic vaccine
- CTN 229
- CTN 237
- CTN 239
- Other studies
- Glossary of terms
- Enrolling
- Research Services